ATRC Stock — AtriCure, Inc.

AtriCure, Inc. (ATRC)

Updated October 16, 2026.

ATRC is a Stock. Total return is 298.2% over the past 21.2 years, 517.3 points behind SPY at 815.5%.

AtriCure develops and manufactures medical devices for cardiac ablation, left atrial appendage exclusion, and peripheral nerve pain treatment, selling its products globally through distributors and direct sales. The company does not currently have an established distribution program. This medical device manufacturer may appeal primarily to growth-oriented investors seeking exposure to the healthcare sector rather than income-focused investors.

ATRC performance versus SPY

Price and return data through 2026-10-16.

Total return is 298.2% over the past 21.2 years, 517.3 points behind SPY at 815.5%. Over the past year its total return — price change plus distributions reinvested — is 50.6%. Its deepest 1-year drawdown was 39.0%.

ATRC key facts

Asset type

Stock

Asset class

Equity

Inception date

08/05/2005

Distribution frequency

None

Last close

$56.07 (as of 2026-10-16)

Market cap

$2,852,073,105

Average volume

648235.0

Beta

1.25

Payout ratio

0.0%

P/E ratio

267.0

Forward P/E

232.5581

EPS

$0.21

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ATRC risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 39.0%.

Who may consider ATRC — and who may not

It is a weaker fit for investors who need monthly cash flow (ATRC does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ATRC

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions